3 US Stocks Including Advanced Energy Industries That May Be Priced Below Estimated Value

In This Article:

As the U.S. stock market navigates a period of fluctuating indices and economic data that has investors closely watching interest rate trends, opportunities may arise for discerning investors to identify stocks priced below their estimated value. In this environment, understanding fundamental metrics and market conditions can be key in recognizing undervalued stocks such as Advanced Energy Industries and others that might offer potential value propositions.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name

Current Price

Fair Value (Est)

Discount (Est)

Clear Secure (NYSE:YOU)

$26.94

$53.02

49.2%

CareTrust REIT (NYSE:CTRE)

$26.42

$51.17

48.4%

Camden National (NasdaqGS:CAC)

$42.01

$83.84

49.9%

Afya (NasdaqGS:AFYA)

$15.03

$29.34

48.8%

Ally Financial (NYSE:ALLY)

$35.78

$69.58

48.6%

HealthEquity (NasdaqGS:HQY)

$98.69

$189.22

47.8%

Constellium (NYSE:CSTM)

$10.47

$20.81

49.7%

TeraWulf (NasdaqCM:WULF)

$6.13

$11.77

47.9%

South Atlantic Bancshares (OTCPK:SABK)

$15.60

$30.73

49.2%

Zillow Group (NasdaqGS:ZG)

$69.67

$136.02

48.8%

Click here to see the full list of 166 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Advanced Energy Industries

Overview: Advanced Energy Industries, Inc. offers precision power conversion, measurement, and control solutions both in the United States and internationally, with a market cap of approximately $4.57 billion.

Operations: The company generates revenue primarily from its Power Electronics Conversion Products segment, which amounts to $1.47 billion.

Estimated Discount To Fair Value: 43.1%

Advanced Energy Industries appears significantly undervalued, trading at US$125.23, notably below its estimated fair value of US$219.96. Despite recent financial challenges, including a net loss of US$14.91 million in Q3 2024 and decreased profit margins from 7.9% to 3.1%, the company forecasts strong earnings growth of 72.1% annually over the next three years, outpacing the broader market's expectations and suggesting potential for future cash flow improvements as markets recover.

NasdaqGS:AEIS Discounted Cash Flow as at Jan 2025
NasdaqGS:AEIS Discounted Cash Flow as at Jan 2025

Repligen

Overview: Repligen Corporation develops and commercializes bioprocessing technologies and systems for biological drug manufacturing globally, with a market cap of $8.63 billion.

Operations: The company's revenue primarily comes from its Medical Products segment, which generated $633.51 million.